Cargando…
Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation
Recently, clinical development of PARP inhibitors (PARPi) expanded from using them as a single agent to combining them with DNA-damaging therapy to derive additional therapeutic benefit from stimulated DNA damage. Furthermore, inhibiting PARP in cancers with BRCA1/2 mutations has been shown to be an...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423503/ https://www.ncbi.nlm.nih.gov/pubmed/30889466 http://dx.doi.org/10.1016/j.redox.2019.101169 |